Hematogenous Osteomyelitis in Childhood Can Relapse Dozens of Years in Adulthood

Completed

• Conditions: Hematogenous Osteomyelitis Relapse; Osteomyelitis

• Registration Number: NCT03898219
• Lead Sponsor: Hospices Civils de Lyon

Brief Summary

To our knowledge, few cases of relapse in adulthood are described in the literature except in patients with sickle cell disease and the epidemiological, clinical, laboratory, radiological features and the management of osteomyelitis relapsing in adulthood are not described. The aim of this retrospective multicentric cohort study : in France is to describe the epidemiological, clinical, laboratory, and radiological features and the management of adult patients who experienced a relapse between 2003-2015 of an acute hematogenous osteomyelitis acquired in the childhood (description of characterization of the period between the first episode of osteomyelitis and the second episode, description of signs of relapse and description of treatments used in the relapse). The data are analysed with non-comparative descriptive statistics.

Detailed Description

Not available

Study Timeline

• Study Start: 2015-01-01
• Primary Completion: 2016-04-06
• Study Completion: 2016-04-06
• Study First Submitted: 2017-06-19
• Status Verified: 2019-03
• Study First Submitted QC: 2019-03-29
• Last Update Submitted: 2019-03-29
• Study First Posted: 2019-04-01
• Last Update Posted: 2019-04-01

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 37

Inclusion Criteria

• Adult patients (≥ 18 years) who presented a relapse between 2003-2015 of a hematogenous osteomyelitis acquired in childhood.
• the time limit between the 2 episodes must be at least 2 years
• antecedent of osteomyelitis before 16 years

Read More

Exclusion Criteria

• inability to give the information to the patient
• patients opposed to the use of their data

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Rate of patients having an osteomyelitis	Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption	Description of the population

Secondary Outcome Measures

Name	Time	Method
rate of management with surgery	Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption	Description of type of surgery
rate of bacteria responsible for infection	Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption	bacterial epidemiology
Rate of Treatment Failure	Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption	Treatment failure is defined by local clinical and/or microbiological relapse; and/or need for additional surgery; death of septic origin

Trial Locations

Locations (1)

Hospices Civils de Lyon - Hopital de la Croix Rousse; 🇫🇷 Lyon, France